The Comparison Between Results of Trabeculectomy With and Without Prior Anti-Vascular Endothelial Growth Factor In Patients With Neovascular Glaucoma at Undaan Eye Hospital Surabaya, Indonesia
Downloads
Introduction: New intraocular medication and anti-vascular endothelial growth factor (VEGF) agents have been developed to manage neovascular glaucoma and surgery. However, no studies compare trabeculectomy with anti-VEGF to no anti-VEGF treatment in patients with neovascular glaucoma. Purpose: This study compares the decrease of intraocular pressure (IOP) between trabeculectomy with and without anti-VEGF in neovascular glaucoma. Methods: This observational study comprised 30 medical records of neovascular glaucoma, divided into 15 medical records of patients with anti-VEGF before trabeculectomy and medical records of patients operated with trabeculectomy without anti-VEGF, monitored between January 2021 and December 2021. Patients with incomplete medical records were excluded. Data collected are age, gender, risk factor, IOP preoperative, and during six months of follow-up IOP postoperative. Data analysis uses an Independent T-test and Mann-Whitney test. Results: From 30 samples, the mean IOP in trabeculectomy with the anti-VEGF group generally is 12.26 mmHg. Meanwhile, the mean IOP in trabeculectomy without the anti-VEGF group generally is 16.74 mmHg. The comparison between two groups shows that there are significant mean differences between them during 1-5 months follow-up (1 month: p = 0.022; 2 months: p = 0.007; 3 months: p = 0.007; 4 months: p = 0.042; and 5 months: p = 0.029). Conclusions: Trabeculectomy with prior administration of intravitreal anti-VEGF shows good IOP reduction and can be implemented in neovascular glaucoma (NVG) patients.
Senthil S, Dada T, Das T, Kaushik S, Puthuran GV, Philip R, et al. Neovascular glaucoma: A review. Indian J Ophthalmol 2021;69:525–534. https://doi.org/10.4103/ijo.IJO_1591_20.
Bai L, Wang Y, Liu X, Zheng Y, Wang W, He N, et al. The optimization of an anti-VEGF therapeutic regimen for neovascular glaucoma. Front Med (Lausanne) 2021;8:766032. https://doi.org/10.3389/fmed.2021.766032.
Dumbraveanu L, Cusnir V, Bobescu D. A review of neovascular glaucoma: Etiopathogenesis and treatment. Rom J Ophthalmol 2021;65:315–329. https://doi.org/10.22336/rjo.2021.66.
Rong AJ, Swaminathan SS, Vanner EA, Parrish RK. Predictors of neovascular glaucoma in central retinal vein occlusion. Am J Ophthalmol 2019;204:62–69. https://doi.org/10.1016/j.ajo.2019.02.038.
Rittiphairoj T, Roberti G, Michelessi M. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev 2023;4:CD007920. https://doi.org/10.1002/14651858.CD007920.pub4.
Tang Y, Shi Y, Fan Z. The mechanism and therapeutic strategies for neovascular glaucoma secondary to diabetic retinopathy. Front Endocrinol (Lausanne) 2023;14:1102361. https://doi.org/10.3389/fendo.2023.1102361.
Mannina A, Olivier M, Patrianakos T. Neovascular glaucoma. Dis Mon 2021;67:101137. https://doi.org/10.1016/j.disamonth.2021.101137.
Havens SJ, Gulati V. Neovascular Glaucoma. Dev Ophthalmol 2016;55:196–204. https://doi.org/10.1159/000431196.
Mishra C, Meyer JJ. Neovascular Glaucoma. StatPearls [Internet] 2022. https://www.ncbi.nlm.nih.gov/books/NBK576393/ (accessed May 30, 2023)
Herdiawan MA. Karakteristik klinis glaukoma neovaskular pada penderita retinopati diabetik di Pusat Mata Nasional Rumah Sakit Mata Cicendo 2016. https://perpustakaanrsmcicendo.com/wp-content/uploads/2017/07/Karakteristik-klinis-glaukoma-neovaskular-pada-penderita-retinopati-diabetik-di-pusat-mata-nasional-rumah-sakit-mata-cicendo.Mohamad-arief-herdiawan.pdf (accessed May 31, 2023).
Rodrigues GB, Abe RY, Zangalli C, Sodre SL, Donini FA, Costa DC, et al. Neovascular glaucoma: A review. Int J Retina Vitreous 2016;2:26. https://doi.org/10.1186/s40942-016-0051-x.
Qiu M, Shukla AG, Sun CQ. Improving outcomes in neovascular glaucoma. Ophthalmol Glaucoma 2022;5:125–127. https://doi.org/10.1016/j.ogla.2021.12.001.
Kim M, Lee C, Payne R, Yue BYJT, Chang J-H, Ying H. Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review. Surv Ophthalmol 2015;60:524–535. https://doi.org/10.1016/j.survophthal.2015.04.003.
Soeprajogo MP. Penggunaan anti-vascular endothelial growth factor dalam terapi glaukoma neovaskular 2019. https://perpustakaanrsmcicendo.com/wp-content/uploads/2019/04/Penggunaan-Anti-Vascular-Endothelial-Growth-Factor-dalam-Terapi-Glaukoma-Neovaskular.magdalena-purnama-soeprajogo.pdf (accessed May 28, 2023).
Slabaugh M, Salim S. Use of anti-VEGF agents in glaucoma surgery. J Ophthalmol 2017;2017:1645269. https://doi.org/10.1155/2017/1645269.
Sun Y, Liang Y, Zhou P, Wu H, Hou X, Ren Z, et al. Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term. BMC Ophthalmol 2016;16:150. https://doi.org/10.1186/s12886-016-0327-9.
Rayess N, Mruthyunjaya P. Anti-vascular endothelial growth factor therapy for radiation retinopathy. Ophthalmic Surg Lasers Imaging Retina 2020;51:S44–49. https://doi.org/10.3928/23258160-20200401-06.
Xie Z, Liu H, Du M, Zhu M, Tighe S, Chen X, et al. Efficacy of ahmed glaucoma valve implantation on neovascular glaucoma. Int J Med Sci 2019;16:1371–1376. https://doi.org/10.7150/ijms.35267.
Simha A, Aziz K, Braganza A, Abraham L, Samuel P, Lindsley KB. Anti-vascular endothelial growth factor for neovascular glaucoma. Coche Dat Syst Rev 2020. https://doi.org/10.1002/14651858.CD007920.pub3.
Ryoo NK, Lee EJ, Kim T-W. Regression of iris neovascularization after subconjunctival injection of bevacizumab. Korean J Ophthalmol 2013;27:299–303. https://doi.org/10.3341/kjo.2013.27.4.299.
Liao N, Li C, Jiang H, Fang A, Zhou S, Wang Q. Neovascular glaucoma: A retrospective review from a tertiary center in China. BMC Ophthalmol 2016;16:14. https://doi.org/10.1186/s12886-016-0190-8.
Olmos LC, Sayed MS, Moraczewski AL, Gedde SJ, Rosenfeld PJ, Shi W, et al. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. Eye (Lond) 2016;30:463–472. https://doi.org/10.1038/eye.2015.259.
Nakatake S, Yoshida S, Nakao S, Arita R, Yasuda M, Kita T, et al. Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: A retrospective analysis. BMC Ophthalmol 2014;14:55. https://doi.org/10.1186/1471-2415-14-55.
Iwasaki K, Kojima S, Wajima R, Okazaki T, Yokoyama Y, Inoue T, et al. Comparing surgical outcomes in neovascular glaucoma between tube and trabeculectomy. Ophthalmol Glaucoma 2022;5:672–680. https://doi.org/10.1016/j.ogla.2022.05.003.
Copyright (c) 2024 Rosalia Adriani Malika, Lydia Nuradianti
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Vision Science and Eye Health Journal by Universitas Airlangga is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The journal allows the author to hold the copyright of the article without restrictions.
The journal allows the author(s) to retain publishing rights without restrictions.
The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Share-Alike (CC BY-SA).
The Creative Commons Attribution-Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violations.
